Capricor Therapeutics, Inc.
Income Statement
| Line Item | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.1M | $2.3M | $4.0M | $4.9M | $12.1M | $6.2M | $3.9M | $3.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $14.6M | $11.8M | $12.5M | $11.1M | $9.9M | $10.0M | $8.8M | $7.7M |
| SG&A Expense | $4.3M | $3.5M | $3.1M | $4.1M | $3.4M | $3.0M | $2.8M | $3.5M |
| Operating Income | $-7.7M | $-13.0M | $-11.6M | $-10.3M | $-1.3M | $-6.9M | $-7.7M | $-8.2M |
| Operating Margin | -69.1% | -575.2% | -291.9% | -209.2% | -10.6% | -111.0% | -197.8% | -274.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-7.1M | $-12.6M | $-11.0M | $-9.8M | $-762.1K | $-6.4M | $-7.4M | $-7.8M |
| Net Margin | -63.9% | -555.2% | -277.0% | -199.6% | -6.3% | -103.3% | -188.0% | -260.1% |
| EPS (Basic) | $-0.11 | $-0.38 | $-0.35 | $-0.31 | $0.02 | $-0.25 | $-0.29 | $-0.31 |
| EPS (Diluted) | $-0.11 | $-0.38 | $-0.35 | $-0.31 | $0.02 | $-0.25 | $-0.29 | $-0.31 |
| Shares Outstanding (Basic) | 35.2M | 33.1M | 31.8M | 31.4M | 26.8M | 25.8M | 25.3M | 25.2M |
| Shares Outstanding (Diluted) | 35.2M | 33.1M | 31.8M | 31.4M | 26.8M | 25.8M | 25.3M | 25.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |